Table 1.
Patient demographics
| Demographic or patient characteristic | BEZ235 200 mg/d + 2.5 mg/d Everolimus (N = 4) |
BEZ235 400 mg/d + 2.5 mg/d Everolimus (N = 7) |
BEZ235 800 mg/d + 2.5 mg/d Everolimus (N = 8) |
Total (N = 19) |
|---|---|---|---|---|
| Age (median, years) | 59 (range 36–64) |
57 (range 54–73) |
52 (range 38–62) |
56 |
| Male | 3 | 3 | 6 | 12 |
| Female | 1 | 4 | 2 | 7 |
| ECOG PS = 0 | 0 | 2 | 1 | 3 |
| ECOG PS = 1 | 4 | 5 | 6 | 15 |
| ECOG PS = 2 | 0 | 0 | 1 | 1 |
| White | 3 | 6 | 6 | 15 |
| Black | 1 | 1 | 1 | 3 |
| Hispanic | 0 | 0 | 1 | 1 |
| # Prior treatments | 3.5 (range 2–5) |
3 (range 2–9) |
3.5 (range 1–5) |
3 (range 1–9) |
| Days of treatment received | 56 (range 18–56) |
19 (range 6–56) |
15 (range 5–46) |
24 (range 5–56) |
| Tumor types | ||||
| NSCLC | 1 | 1 | 0 | 2 |
| Brain tumor | 1 | 1 | 1 | 3 |
| Colon carcinoma | 1 | 1 | 1 | 3 |
| HCC | 1 | 0 | 0 | 1 |
| Pancreatic Ca | 0 | 1 | 0 | 1 |
| Esophageal Ca | 0 | 1 | 1 | 2 |
| Laryngeal ca (adenoid cystic) | 0 | 1 | 0 | 1 |
| Appendix ca | 0 | 1 | 0 | 1 |
| HNSCC | 0 | 0 | 1 | 1 |
| Prostate ca | 0 | 0 | 1 | 1 |
| Ovarian ca | 0 | 0 | 1 | 1 |
| Rectal NET | 0 | 0 | 1 | 1 |
| Endometrial Ca | 0 | 0 | 1 | 1 |